Some of the world's largest biopharmaceutical products, among the highest revenue generators in the pharmaceutical industry, may face competition from so-called "biosimilars," according to a new report from healthcare market research firm Kalorama Information.
Philadelphia Agenda Announcement and Advisory Board Introduction
November 20, 2017, Erie, PA: Life Science Leader and ClinicalLeader.com are excited to announce that Clinical Leader Forum will take place in Boston and Philadelphia in 2018. The Boston event is scheduled for October 3 – 4, 2018 at the State Room Boston. The Philadelphia event is scheduled for May 9-10, 2018 at the Hilton Philadelphia City Avenue.
Samsung Bioepis Co., Ltd. recently announced the European Commission’s (EC) marketing authorization of ONTRUZANT, a biosimilar referencing Herceptin (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer.
The "Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - a 2017 Update" report has been added to Research and Markets' offering.
Today, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that includes a number of changes that, if finalized, will ensure that Part D Medicare enrollees have access to more affordable prescription drugs and more robust prescription drug coverage at the pharmacy they prefer.
British Columbia and Prince Edward Island are the first provinces to add Erelzi (etanercept) to their public drug plans for the treatment of multiple inflammatory diseases, respectively on November 14 and November 27.
The Competitive Intelligence Report "Anti-VEGF & Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update" provides a competitor evaluation in the field of recombinant antibodies, proteins and vaccines targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) for treatment of a variety of cancer indications and retinal diseases as of November 2017.
THERADIAG (ISIN code: FR0004197747, Ticker: ALTER) a company specialized in in vitro diagnostics and theranostics, is recently announcing that it has entered into a partnership agreement with Biogen to provide its LISA TRACKER kits for monitoring Flixabi (an infliximab biosimilar).
Sandoz, a Novartis division and the global leader in biosimilars, today announces data from four clinical studies comparing its proposed biosimilar adalimumab and biosimilar rituximab with their reference medicines, Humira and MabThera/Rituxan respectively.